Catalyst Wire Dossier Catalyst Wire Dossier

Boserolimab

boserolimab · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Boserolimab, covering 2025-11-05 to 2026-02-19. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) [Phase 2]

See pricing